Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
Anticancer Research · 2023
DOI: 10.21873/anticanres.16241 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, 2023. Verfasst von Ioannis A Voutsadakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, ON, Canada; ivoutsadakis@nosm.ca. Hauptthemen laut MEDLINE: Breast Neoplasms, Genes, BRCA2. Die Arbeit wurde bisher 31-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, ON, Canada; ivoutsadakis@nosm.ca.
- Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada.
- Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Zitieren
APA
Voutsadakis, I. A., & Stravodimou, A. (2023). Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. Anticancer Research. https://doi.org/10.21873/anticanres.16241
Vancouver
Voutsadakis IA, Stravodimou A. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. Anticancer Research. 2023. doi:10.21873/anticanres.16241
BibTeX
@article{Voutsadakis2023,
author = {Voutsadakis, Ioannis A and Stravodimou, Athina},
title = {Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16241}
}
EUVIMED